A new solution for doctors and painkillers
Independent Investment Research
QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to...
There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session with the FDA's Advisory...
Canaccord Genuity Australia